Johnson & Johnson has decided to pause vaccinations in all of its clinical trials while they “update guidance for investigators and participants,” according to a statement from the company on Tuesday.
The announcement follows a recommendation from US Centers for Disease Control and Prevention and the US Food and Drug Administration to pause the use of the Johnson & Johnson vaccine over blood clot concerns out of an “abundance of caution.”
The company also announced earlier that it would “proactively delay the rollout of our vaccine in Europe.”
The company currently has several ongoing trials including an ongoing Phase 2a trial and a Phase 3b trial in South Africa.
The Phase 2a trial has been ongoing since September and was initially designed to study single-dose and two-dose regimens of the vaccine, at different dose levels and schedules, in healthy adults ages 18 to 55 and 65 and older. The study expanded this study to adolescents age 12 to 17 on April 2.